Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents

Keyphrases

• Angioedema Attack 100%
• Hereditary Angioedema 100%
• Long-term Prophylaxis 60%
• Naïve Patients 30%
• Open-label Extension 30%
• Angioedema 20%
• Quality of Life Questionnaire 20%
• Treatment-related 20%
• Adolescent Patients 20%
• Long-term Efficacy 10%
• Health-related Quality of Life 10%
• Placebo-controlled 10%
• Trial Registration 10%
• Treatment Satisfaction 10%
• Serious Adverse Events 10%
• Treatment Level 10%
• Clinically Meaningful Improvement 10%
• Subgroup Analysis 10%
• Patient-reported Outcomes 10%
• Treatment-related Adverse Events 10%
• Attack Rate 10%

Medicine and Dentistry

• Hereditary Angioedema 100%
• Adolescence 100%
• Quality of Life 30%
• Adverse Event 20%
• Angioedema 20%
• Placebo 10%
• Single Drug Dose 10%
• Subgroup Analysis 10%
• Patient-Reported Outcome 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Angioneurotic Edema 100%
• Lanadelumab 100%
• Adverse Event 16%
• Placebo 8%